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Abstract
Background: The interleukin-6 (IL-6) pathway is one of the mechanisms that link inflammation
and angiogenesis to malignancy. Because the C-reactive protein (CRP) is a representative marker
for inflammation, CRP has recently been associated with the progression of disease in many cancer
types. The principal objective of this study was to determine the preoperative serum levels of IL-6
and CRP in gastric carcinoma, and to correlate them with disease status and prognosis.
Methods: A total of 115 patients who underwent gastrectomy were enrolled in this study. Serum
levels of IL-6 were assessed via Enzyme-Linked Immuno-Sorbent Assay (ELISA), and CRP was
measured via immunoturbidimetry. Histological findings included tumor size, depth of tumor
invasion, lymph node (LN) metastasis, and TNM stage (6th AJCC Stage Groupings: The staging
systems; Primary tumor, regional LN, metastasis).
Results:  Increases in cancer invasion and staging are generally associated with increases in
preoperative serum IL-6 levels. IL-6 and CRP levels were correlated with invasion depth (P < 0.001,
P = 0.001), LN metastasis (P < 0.001, P = 0.024) and TNM stage (P < 0.001, P < 0.001). The presence
of peritoneal seeding metastasis is associated with IL-6 levels (P = 0.012). When we established the
cutoff value for IL-6 level (6.77 pg/dL) by ROC curve, we noted significant differences in time to
progression (TTP; P < 0.001) and overall survival (OS; P = 0.010). However, CRP evidenced no
significance with regard to patients' TTP and OS levels. Serum IL-6 levels were correlated positively
with CRP levels (r2 = 0.049, P = 0.018).
Conclusion: Preoperative serum IL-6 and CRP levels might be markers of tumor invasion, LN
metastasis, and TNM stage. Preoperative high IL-6 levels were proposed as a poor prognostic
factor for disease recurrence and overall survival in patients with gastric cancers.
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Background
Interleukin-6 (IL-6) is a multi-poietic cytokine that
induces the growth and differentiation of immune cells,
the production and expression of other cytokines, and
acute-phase protein synthesis. IL-6 also exerts several
effects on cancer cells [1,2].
In cancer, IL-6 is generally known to be involved in host
defense mechanisms. IL-6 binds to the IL-6 receptor, acti-
vates the Janus kinase (JAK), and subsequently phosphor-
ylates the signal transducers and activators of
transcription (STAT). The phosphorylated STAT gene
translocates into the nucleus and activates the target gene
(JAK/STAT) pathway. Suppressor of cytokine signaling-1
(SOCS-1) is one of the STAT-activated genes, which is
upregulated by IL-6 and is involved in the downregulation
of the JAK/STAT pathway [3-5]. In many cancer types,
recent studies have demonstrated that the hypermethyla-
tion of SOCS-1 is not controlled by the JAK/STAT path-
way, and IL-6 cannot perform a role in cancer defense; on
the contrary, it is involved in cancer development [3,6].
In the development and progression of cancer, angiogen-
esis is a crucial and essential process. IL-6 is associated
with angiogenesis by virtue of its ability to induce the
mRNA of vascular endothelial growth factor (VEGF),
which is typically a direct angiogen [1]. Additionally, IL-6
activates the Rho protein, which is associated with cell-cell
adhesion and invasion in malignancy [7].
C-reactive protein (CRP) is a representative marker for
inflammatory conditions, and performs a crucial anti-
infection function in the immune system. In many can-
cers, it has been reported that chronic inflammation is
involved with malignant change, and the risks of cancer
are increased when pre-diagnostic CRP levels are high [8].
Cancer invasion begins with inflammation around cancer
cells. Thus, it has been reported that serum CRP levels are
higher in cases of invasive cancer than in cases of non-
invasive cancer [9,10].
Gastric cancer is the fourth most-frequent source of mor-
bidity worldwide, and the second most-frequent source of
mortality [11,12]. In Korea, gastric cancer is the most fre-
quent source of morbidity among malignant tumors [13].
These high levels of gastric cancer mortality can be attrib-
uted to the high incidence of serosal invasion, direct inva-
sion into the adjacent organs, peritoneal seeding, lymph
node metastasis, and distant metastasis of gastric cancer.
In cases of gastric cancer, the failure of downregulation of
the JAK/STAT pathway due to the hyper-methylation of
SOCS-1 has been surveyed, and angiogenesis has been
identified as an indispensable process for high tendencies
toward malignancy [3,14,15]. The principal objective of
this study was to determine the relationship between
serum IL-6 and CRP levels and malignant tendencies and
prognosis in gastric cancer patients.
Methods
Patients
From March 2005 to August 2008, a total of 115 patients
with histologically-confirmed gastric carcinomas from
surgically resected specimens of gastric tumors at the
Dong-A University Hospital were enrolled in this study.
After operation, the disease status of patients was evalu-
ated via gastroendoscopy and abdominal computed tom-
ography (CT). During the first 2 years, we checked CT and
endoscopy at six-month intervals, and afterwards CT and
endoscopy were conducted every 12 months. We also con-
ducted abdomen CT when we observed abdominal dis-
tension, acute abdominal pain, severe diarrhea, and chest
X-ray abnormalities suggestive of lung metastasis. Endos-
copy was conducted in cases in which patients com-
plained of unexplained abdominal discomfort and
dyspepsia. On average, in the stage III and IV patients, the
first evaluation was conducted within 3 months after
operation. All patients provided informed consent, and
the hospital review board approved the study.
Assay of serum IL-6 and CRP
Venous blood sampling was conducted within 7 days
before the patients underwent operations. The blood col-
lected for IL-6 serum level assessments was collected in
plain tubes, and the levels of serum IL-6 were measured
using commercially available enzyme-linked immuno-
sorbent assays (ELISAs) (Quantikine h IL-6 Immu-
noassay, R&D Systems, USA). The blood samples were
centrifuged for 10 min at 3,000 r/min at -4°C. The serum
was subsequently removed and stored at -80°C until bio-
chemical analysis. The blood samples for CRP analysis
were collected in serum separation tubes, and the serum
CRP levels were measured via immunoturbidimetry
(Denka Seiken Co. Ltd., Japan).
Statistical analysis
Serum levels of IL-6 and CRP were expressed as the means
± SD. A p value of < 0.05 was considered to be statistically
significant. The Spearman rho correlation coefficient (r)
was employed to evaluate the correlation between the IL-
6 and CRP levels and the clinical findings. The IL-6 and
CRP cut-off values for survival analysis were determined
by the ROC curve. The duration of recurrence of gastric
cancer and death measured from the date of surgery was
referenced against time to progression and overall survival
time. Survival durations were calculated via the Kaplan-
Meier method. The log-rank test was employed to com-
pare the cumulative survival rate and time to progression
in the patient groups. Linear regression analysis was con-
ducted to estimate the relationship between the IL-6 val-
ues and CRP values. The Statistical Package for SocialBMC Cancer 2009, 9:155 http://www.biomedcentral.com/1471-2407/9/155
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Sciences (SPSS) Version 15.0 for Windows was utilized to
perform all statistical analyses.
Results
Patients' characteristics
The patients were classified by their pathologic character-
istics, including tumor size, depth of tumor invasion, sta-
tus of lymph node metastasis, TNM staging, and
peritoneal metastasis. The patients consisted of 68 men
and 47 women, with a median age of 59 years (range, 33–
84 years). The characteristic data of the study population
are shown in Table 1. 53 patients evidenced tumor sizes of
≥ 5 cm. The depth of tumor invasion was pT1 in 29
patients, pT2 in 48, pT3 in 32, and pT4 in 6. LN metastasis
was detected in 73 patients. The postoperative stages of
the patients were I, II, III, and IV in 43, 23, 30, and 19
patients, respectively. Six patients in this study had perito-
neal metastasis.
Clinicopathological significance of IL-6
The relationships between IL-6, CRP levels, and clinico-
pathologic variables are provided by the Spearman rho
correlation coefficient (r) in Table 2.
We noted that IL-6 levels were significantly correlated
with IL-6 levels, and tumor size with higher IL-6 levels was
detected in tumors sized ≥ 5 cm (P = 0.0012). Addition-
ally, with increasing degrees of tumor invasion, the
median levels of IL-6 evidenced a tendency to increase,
and this difference in IL-6 levels was found to be statisti-
cally significant (P < 0.001). In cases of LN metastasis, we
also noted a significant difference between the serum level
of IL-6 and LN metastasis (P < 0.001). The median level of
IL-6 increased proportionally with the stage of the cancer
(the median level of IL-6 in stage I 7.36 ± 5.52 pg/ml,
stage II 7.66 ± 2.24 pg/ml, stage III 11.87 ± 14.90 pg/ml
and stage IV 13.92 ± 10.76 pg/ml), and this difference was
statistically significant (P < 0.001). Additionally, serum
IL-6 levels were significantly higher in patients with peri-
toneal metastasis (23.70 ± 14.55 pg/ml) than in those
without peritoneal seeding (6.83 ± 8.83 pg/ml, P = 0.012)
(Figure 1).
The patients were divided into two groups on the basis of
an IL-6 cutoff value of 6.77 pg/ml by the ROC curve with
a sensitivity of 85.7% and a specificity to OS of 50.1%.
The TTP values for patients with IL-6 levels in excess of
6.77 pg/ml were significantly lower than those in patients
with IL-6 values of 6.77 pg/ml or less (60.0% versus
88.7%; P = 0.0004) (Figure 2). We also noted significant
differences in the OS values (80.7% versus 96.2%; P =
0.010) (Figure 3). However, in multivariate analysis used
to age, gender TNM stage, tumor size and peritoneal
metastasis, TTP and OS showed that IL-6 was not related
to TTP and OS.
Clinicopathological significance of CRP
We noted that CRP levels did not differ significantly with
tumor size (P = 0.039) However, levels of CRP were asso-
ciated with tumor invasion depth (P = 0.001). We also
noted significant differences in serum CRP levels between
patients with lymph node metastasis and those without
lymph node metastasis (P = 0.024). The median levels of
CRP increased with increasing stage, and we also noted
significant differences between the CRP level and cancer
stage (the median level of CRP in stage I 0.06 ± 0.29 mg/
dl, stage II 0.07 ± 0.15 mg/dl, stage III 0.12 ± 0.30 mg/dl
and stage IV 0.39 ± 0.50 mg/dl; P < 0.001). The CRP levels
did not differ significantly in patients with peritoneal
metastasis (0.41 ± 0.69 mg/dl) as compared to those with-
out peritoneal metastasis (0.08 ± 0.29 mg/dl, P = 0.061)
(Figure 4).
0.145 mg/dl was taken as the cutoff value of CRP by ROC
curve, after which the patients were divided into two
groups. The sensitivity and specificity of 0.145 mg/dl as
the cutoff value were 57.1% and 65.3% on OS. We noted
no significant difference in the TTP values (70.7% vs
75.0%, P = 0.5245) and OS values (81.4% vs 91.7%, P =
0.0791) among the groups.
Table 1: Patient characteristics
No. of patients %
Total number of patients 115
Sex
Male 68 59.1
Female 47 40.1
Age
Median(Range) 59(33–84)
Tumor size
< 5 62 53.9
≥ 55 3 4 6 . 1
Depth of tumor invasion
pT1 29 25.2
pT2 48 41.8
pT3 32 27.8
pT4 6 5.2
LN metastasis
N0 42 36.5
N1 43 37.4
N2 18 15.7
N3 12 10.4
Peritoneal metastasis
Metastasis(-) 109 94.8
Metastasis(+) 6 5.2
TNM stage
Stage I 43 37.4
Stage II 23 20.0
Stage III 30 26.1
Stage IV 19 16.5BMC Cancer 2009, 9:155 http://www.biomedcentral.com/1471-2407/9/155
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Association between IL-6 and CRP
Serum IL-6 levels were positively correlated with CRP lev-
els (r2 = 0.049, P = 0.018) (Figure 5).
Discussion
In this study, the serum levels of both IL-6 and CRP evi-
denced statistically significant differences in tumor size,
tumor invasion depth, and LN metastasis. In the TNM
stage, as the stage of the disease increased, serum IL-6 and
CRP levels were significantly higher. Additionally, the
median levels of IL-6 were significantly higher in the
patients with peritoneal seeding than in those without
peritoneal seeding, but in CRP, this was not proven. In
terms of survival rate and time to cancer progression, the
results of this study showed that IL-6 levels were associ-
ated with poor prognoses. As IL-6 and CRP levels were
associated strongly with disease status, in our multivariate
analysis, IL-6 and CRP were not identified as independent
factors. In some papers, it has been reported that IL-6 was
an effective prognostic indicator in stages II and III [16].
In this study, we conducted multivariate analysis in stage
II and III, but we were unable to detect any tendency that
would point to IL-6 as an independent prognostic factor.
There have been a great many studies conducted concern-
ing the values and functions of IL-6 in malignancy. The
majority of these studies have shown that IL-6 levels were
higher in malignancies than in non-malignancies, and
increased with increasing tumor size and depth [17-19].
We detected a statistically significant relationship between
IL-6 levels and existing LN metastasis. However, some
studies have reported no relationship between IL-6 levels
and LN metastasis [20]. LN metastasis was shown to be
affected by independent predictors in cases of advanced
cancers. Many previous studies have also noted that IL-6
levels increased in cases of distant metastasis, especially
hepatic metastasis [17,18]. This result has been attributed
to a host of mechanisms, including the autocrine and
paracrine pathways. With regard to the autocrine path-
way, IL-6 activated the production of IL-6 by tumor cells
Table 2: Correlation between the IL-6, CRP and clinicopathological parameters
IL-6 CRP
Median ± SD rP Median ± SD RP
Total pg/ml (mg/dl)
Gender
Male 6.83 ± 7.34 0.082 0.385 0.11 ± 0.25 -0.076 0.421
Female 7.07 ± 12.30 0.06 ± 0.43
Age
<60 6.48 ± 12.26 0.205 0.028 0.07 ± 0.30 0.152 0.104
≥ 60 7.31 ± 5.56 0.11 ± 0.38
Tumor size
<5 cm 6.48 ± 5.04 0.235 0.012 0.09 ± 0.28 0.081 0.389
≥5 cm 7.56 ± 12.93 0.09 ± 0.39
Tumor depth
pT1 6.25 ± 1.41 0.387 0.000 0.05 ± 0.10 0.311 0.001
pT2 6.60 ± 5.42 0.07 ± 0.31
pT3 7.62 ± 16.02 0.17 ± 0.36
pT4 9.76 ± 6.06 0.64 ± 0.64
LN meta
N0 6.36 ± 5.61 0.322 0.000 0.06 ± 0.30 0.211 0.024
N1 7.70 ± 13.99 0.11 ± 0.36
N2 6.83 ± 2.10 0.09 ± 0.08
N3 7.80 ± 6.96 0.19 ± 0.51
(N1–N3) 7.56 ± 11.24 0.338 0.000 0.11 ± 0.35 0.212 0.023
TNM stage
I 7.36 ± 5.52 0.425 0.000 0.06 ± 0.29 0.326 0.000
II 7.66 ± 2.24 0.07 ± 0.15
III 11.87 ± 14.90 0.12 ± 0.30
IV 13.92 ± 10.76 0.39 ± 0.50
Peritoneal
Metastasis(-) 6,83 ± 8.83 0.233 0.012 0.08 ± 0.29 0.175 0.061
Metastasis(+) 23.70 ± 14.55 0.41 ± 0.69
r, P: Spearman rho correlation, IL-6: interleukin-6, CRP: C-reactive protein, LN: lymph node, TNM (6th AJCC Stage Groupings: The staging systems; 
Primary tumor, regional LN, metastasis)BMC Cancer 2009, 9:155 http://www.biomedcentral.com/1471-2407/9/155
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(A) IL-6 levels according to tumor depth Figure 1
(A) IL-6 levels according to tumor depth. (B) IL-6 levels according to LN metastasis. (C) IL-6 levels according to the 
TNM stage. (D) IL-6 levels according to peritoneal metastasis. °, mild outlier (between 1.5 interquartile range (IQR) and 3.0 
IQR); *, extreme outlier (more than 3.0 IQR).BMC Cancer 2009, 9:155 http://www.biomedcentral.com/1471-2407/9/155
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with the IL-6 receptor. With regard to the paracrine path-
way, IL-6-stimulated stromal cells promoted the secretion
of tumor growth and adhesion molecules containing
VEGF and hepatocyte growth factor (HGF) [2,17,19,21].
CRP has been identified in many previous studies as a
poor prognostic factor in several diseases, including coro-
nary artery disease, chronic obstructive pulmonary dis-
ease, diabetes mellitus, myeloma bone disease, and a
variety of cancers [22-30]. In many studies of cancer
patients, it has been noted that elevated CRP levels are
associated with tumor size, cancer stage, cancer cachexia,
and poor prognosis as independent prognostic indicators
[19,26,28,31]. In this paper, we described the relationship
between CRP levels and tumor invasion depth, LN metas-
tasis, and TNM stage. The operant mechanism in this
regard remains unknown. However, elevations of CRP
levels have been reported previously in patients with
impaired T lymphocyte response, and thus this mecha-
nism is considered to be related to the immunity system
and poor survival rate [31].
CRP is generated by the liver and other organs in response
to the release of IL-6 by monocytes and other immune
cells [26]. Thus, when IL-6 levels increased, CRP levels
also increased. Although CRP was not found, in this
study, to be related to TTP and OS in cancer patients, CRP
has generally been connected with IL-6, and IL-6 is associ-
ated with cancer prognosis. This study was somewhat lim-
ited in that the patients' group was restricted in patients
who underwent operations. Thus, this study included
more patients who could undergo surgery at a lower stage
than those who evidenced contraindications for curative
operations, including those patients in stage IV. In partic-
ular, as compared with another study concerning the rela-
tionship between CRP levels and cancer prognosis, a
small number of advanced-stage patients were enrolled in
this study [27].
Elevated serum IL-6 levels have been implicated in many
different conditions characterized by chronic inflamma-
tion, including viral and bacterial infections, autoimmune
disease, ischemia, diabetes mellitus, severe exercise, and
malignancy [6,32]. Actually, when the IL-6 cutoff value
was established at 6.77 pg/ml, the TTP and OS differed
Time to progression curve according to interleukin-6 (IL-6)  level Figure 2
Time to progression curve according to interleukin-6 
(IL-6) level.
Overall survival curve according to interleukin-6 (IL-6) level Figure 3
Overall survival curve according to interleukin-6 (IL-
6) level.BMC Cancer 2009, 9:155 http://www.biomedcentral.com/1471-2407/9/155
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(A) CRP levels according to tumor depth Figure 4
(A) CRP levels according to tumor depth. (B) CRP levels according to LN metastasis. (C) CRP levels according to TNM 
stage. (D) CRP levels according to peritoneal metastasis. °, mild outlier (between 1.5 interquartile range (IQR) and 3.0 IQR); *, 
extreme outlier (more than 3.0 IQR).BMC Cancer 2009, 9:155 http://www.biomedcentral.com/1471-2407/9/155
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significantly between patients with IL-6 levels in excess of
6.77 pg/ml, and those with lower IL-6 levels. When the IL-
6 cutoff value was established at 6.77 pg/ml, the sensitiv-
ity was 80.0% in TTP and 85.7% in OS; the specificity was
55.3% and 50.1%. Although there were many disturbance
factors that complicated the elevation of IL-6 levels, the
sensitivity of IL-6 in association with TTP and OS was
found, in this study, to be sufficiently high. Thus, we sur-
mise that the prognoses in gastric cancer patients with
high IL-6 levels would be generally poor.
However, high IL-6 and CRP levels were related to
advanced stage, including distant metastasis, in this study,
and elevated IL-6 levels were associated with poor out-
comes in cases of gastric cancer.
Conclusion
Preoperative serum IL-6 and CRP levels were related to
cancer stage and might be markers of tumor invasion, LN
metastasis and TNM stage. Especially high IL-6 levels were
prospected as a poor prognostic factor of disease recur-
rence and overall survival in patients with gastric cancer.
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